Morgan Stanley Assumes Halozyme Therapeutics (HALO) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 128.80 +0.18 (0.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.62 | 52 Week High | $18.39 | |||
| Open | $130.81 | 52 Week Low | $6.96 | |||
| Day High | $130.81 | P/E | N/A | |||
| Day Low | $128.32 | EPS | $-0.58 | |||
| Volume | 313,634 | |||||
